Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.56M | $7.81M | $5.99M | $5.82M | $5.11M | — |
| Revenue growth | — | -18.3% | -23.3% | -2.8% | -12.2% | — |
| Gross profit | $5.51M | $6.21M | $3.70M | $4.19M | $3.90M | — |
| Gross margin | 57.7% | 79.5% | 61.8% | 72.0% | 76.3% | — |
| Operating income | -$17.3M | -$18.0M | -$19.9M | -$13.6M | -$4.63M | -$4.64M |
| Operating margin | -180.8% | -231.1% | -332.4% | -233.9% | -90.5% | — |
| Net income | -$20.6M | -$8.99M | -$20.0M | -$8.16M | -$14.3M | $1.91M |
| Net margin | -215.3% | -115.0% | -334.4% | -140.2% | -280.1% | — |
| EPS (diluted) | -$3.85 | -$8.25 | -$9.68 | -$6.35 | -$83.47 | -$1.56 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15.3M | -$11.9M | -$12.8M | -$7.63M | -$2.60M | -$6.73M |
| Capital expenditures | $4.63K | — | — | — | $24.6K | — |
| Free cash flow | -$15.3M | — | — | — | -$2.63M | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.1M | $23.8M | $9.43M | $13.3M | $1.72M | $5.14M |
| Total assets | $69.9M | $67.4M | $32.4M | $33.8M | $10.6M | $5.16M |
| Total liabilities | $52.4M | $31.8M | $15.7M | $21.3M | $18.1M | $2.29M |
| Shareholders' equity | $17.5M | $35.5M | $16.7M | $12.1M | -$7.47M | $2.87M |
| Retained earnings | -$61.7M | -$70.7M | -$90.7M | -$98.9M | -$113M | -$111M |
| Shares (wtd avg diluted) | 5.34M | 1.09M | 2.07M | 2.18M | 321K | 28.1M |
Every figure is extracted from Petros Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.